Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Foghorn Therapeutics Inc (FHTX)

Foghorn Therapeutics Inc (FHTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 523,397
  • Shares Outstanding, K 36,937
  • Annual Sales, $ 430 K
  • Annual Income, $ -68,800 K
  • 60-Month Beta N/A
  • Price/Sales 1,159.65
  • Price/Cash Flow N/A
  • Price/Book 4.85
Trade FHTX with:

Options Overview Details

View History
  • Implied Volatility 109.54%
  • Historical Volatility 63.15%
  • IV Percentile 68%
  • IV Rank 74.16%
  • IV High 142.79% on 08/17/21
  • IV Low 14.13% on 08/06/21
  • Put/Call Vol Ratio 3.00
  • Today's Volume 8
  • Volume Avg (30-Day) 1
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 7
  • Open Int (30-Day) 2

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.66
  • Number of Estimates 2
  • High Estimate -0.63
  • Low Estimate -0.68
  • Prior Year -3.12
  • Growth Rate Est. (year over year) +78.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.01 +43.26%
on 08/25/21
14.48 -0.97%
on 09/10/21
+4.01 (+38.82%)
since 08/20/21
3-Month
8.01 +79.03%
on 08/10/21
14.48 -0.97%
on 09/10/21
+4.03 (+39.09%)
since 06/22/21

Most Recent Stories

More News
Coupa Software (COUP) Q2 Earnings & Revenues Top Estimates

Coupa Software's (COUP) second-quarter fiscal 2022 results reflect continued strength in the uptake of the company's solutions including Business Spend Management and Coupa Supply Chain Management.

ORCL : 88.44 (+1.75%)
WD : 111.11 (+2.39%)
COUP : 243.62 (unch)
FHTX : 14.34 (+1.20%)
Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer

The FDA grants an Orphan Drug designation to Aldeyra's (ALDX) ADX-2191 for the treatment of primary vitreoretinal lymphoma.

CORT : 20.27 (+0.10%)
CANF : 1.6667 (+1.01%)
ALDX : 8.14 (+2.52%)
FHTX : 14.34 (+1.20%)
Flagship Pioneering Closes $3.4 Billion Capital Pool to Drive Continued Breakthrough Innovations in Human Health and Sustainability

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced a significant expansion of its capital base to support founding and growing its next generation of human health...

FHTX : 14.34 (+1.20%)
SANA : 22.38 (-5.57%)
SGTX : 5.42 (-0.73%)
AXLA : 3.07 (-2.54%)
CDAK : 18.05 (-4.45%)
EVLO : 7.39 (+3.07%)
KLDO : 5.69 (-0.52%)
MRNA : 440.72 (+1.54%)
RUBY : 19.31 (-0.82%)
MCRB : 7.02 (+1.59%)
Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture

, /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental...

AXLA : 3.07 (-2.54%)
CDAK : 18.05 (-4.45%)
DNLI : 51.98 (-2.33%)
EVLO : 7.39 (+3.07%)
FHTX : 14.34 (+1.20%)
KLDO : 5.69 (-0.52%)
MCRB : 7.02 (+1.59%)
MRNA : 440.72 (+1.54%)
RUBY : 19.31 (-0.82%)
SANA : 22.38 (-5.57%)
SGTX : 5.42 (-0.73%)
Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening

, /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental...

AXLA : 3.07 (-2.54%)
CDAK : 18.05 (-4.45%)
DNLI : 51.98 (-2.33%)
EVLO : 7.39 (+3.07%)
FHTX : 14.34 (+1.20%)
KLDO : 5.69 (-0.52%)
MCRB : 7.02 (+1.59%)
MRNA : 440.72 (+1.54%)
RUBY : 19.31 (-0.82%)
SANA : 22.38 (-5.57%)
SGTX : 5.42 (-0.73%)
Is a Surprise Coming for Foghorn Therapeutics (FHTX) This Earnings Season?

Foghorn Therapeutics (FHTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

FHTX : 14.34 (+1.20%)
Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer

, /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental...

AXLA : 3.07 (-2.54%)
CDAK : 18.05 (-4.45%)
DNLI : 51.98 (-2.33%)
EVLO : 7.39 (+3.07%)
FHTX : 14.34 (+1.20%)
KLDO : 5.69 (-0.52%)
MRNA : 440.72 (+1.54%)
RUBY : 19.31 (-0.82%)
SANA : 22.38 (-5.57%)
MCRB : 7.02 (+1.59%)
SGTX : 5.42 (-0.73%)
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target

, /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised in Series B financing....

AXLA : 3.07 (-2.54%)
CDAK : 18.05 (-4.45%)
DNLI : 51.98 (-2.33%)
EVLO : 7.39 (+3.07%)
FHTX : 14.34 (+1.20%)
KLDO : 5.69 (-0.52%)
MRNA : 440.72 (+1.54%)
RUBY : 19.31 (-0.82%)
SANA : 22.38 (-5.57%)
MCRB : 7.02 (+1.59%)
SGTX : 5.42 (-0.73%)
Flagship Pioneering Unveils Pioneering Medicines

, /PRNewswire/ -- Flagship Pioneering, a life science platforms company, today unveiled Pioneering Medicines, a new division of Flagship Pioneering. Initiated in 2020, Pioneering Medicines' mandate is...

FHTX : 14.34 (+1.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Foghorn Therapeutics Inc. engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 15.46
2nd Resistance Point 14.96
1st Resistance Point 14.65
Last Price 14.34
1st Support Level 13.84
2nd Support Level 13.34
3rd Support Level 13.03

See More

52-Week High 28.26
Fibonacci 61.8% 20.53
Fibonacci 50% 18.14
Fibonacci 38.2% 15.75
Last Price 14.34
52-Week Low 8.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar